Interim Data From A Clinical Trial Evaluating GI Dynamics' EndoBarrier™ Gastrointestinal Liner In Patients With Type 2 Diabetes
Published at: www.medicalnewstoday.com
-
Effective Obesity Treatment with a Removable Medical Device
December 1, 2009
Promising new medical strategy, in clinical trials, with intriguing worldwide application, but especially in Western markets.
-
William HaynesDirector of Clinical PharmacologyTHE UNIVERSITY OF IOWA
EndoBarrier has Potential for Treatment of Obesity and Type 2 Diabetes Mellitus
November 30, 2009
Endoscopic placement of the EndoBarrier reduces weight by 14% and HBA1c by 1.5% after 24 weeks. While not reaching the magnitude of weight loss from bariatric surgery, these changes are impressive and substantially exceed those seen with pharmacologic monotherapy. If this efficacy is validated in future trials, and there are no safety issues, this approach could be useful for a large number of obese patients.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.